<DOC>
	<DOCNO>NCT00002228</DOCNO>
	<brief_summary>The purpose study see safe effective give T-20 HIV-positive adult . T-20 anti-HIV drug .</brief_summary>
	<brief_title>A Study T-20 HIV-Positive Adults</brief_title>
	<detailed_description>Patients randomly place 1 6 group : 4 dose level T-20 give subcutaneous infusion 2 subcutaneous injection . The entire study last 7 week ; include 2-week screening period , follow 28 day treatment 1 week follow-up .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Enfuvirtide</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Any antiretroviral agent , provide regimen change within 6 week screen visit . Antibiotics bacterial infection . Prophylactic medication P. carinii pneumonia M. avium , include azithromycin . Medications symptomatic treatment antipyretic , analgesic , antiemetic . Patients must : HIV1 seropositive status . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Concurrent neoplasm ( except basal cell carcinoma skin , situ carcinoma cervix , nondisseminated stable Kaposi 's sarcoma ) . Concurrent Medication : Excluded : Patients must take concurrent antiretroviral therapy ( least 2 week prior baseline ) patient stable antiretroviral regimen change least 6 week prior baseline . Treatment follow : immunomodulators , biological response modifier , chemotherapy discontinue duration study , astemizole , terfenadine , cisapride , triazolam , midazolam , rifampin , clarithromycin , investigational drug within 30 day prior initial visit . Patients follow prior condition exclude : Evidence active opportunistic infection , unexplained temperature great equal 38.5 Celsius 7 consecutive day within 30 day prior screen visit . Chronic diarrhea ( define great 3 liquid stool per day persist 15 day ) within 30 day prior screen visit . Diagnosis hemophilia clot disorder . Prior Medication : Excluded : Prior treatment HIV vaccine . Prior Treatment : Excluded : Major organ allograft . Risk Behavior : Excluded : Evidence substance abuse addiction , opinion investigator , may interfere patient 's ability comply dose schedule protocol evaluation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 1999</verification_date>
	<keyword>Injections , Subcutaneous</keyword>
	<keyword>HIV-1</keyword>
	<keyword>Anti-HIV Agents</keyword>
	<keyword>peptide T20</keyword>
</DOC>